Influence of Obesity on Outcomes in Atrial Fibrillation: Yet Another Obesity Paradox

American Journal of Medicine

Volumn 123, Issue 7, 2010, Pages 646-651

  Badheka, Apurva O ^a   Rathod, Ankit ^a   Kizilbash, Mohammad A ^a   Garg, Neha ^a   Mohamad, Tamam ^a   Afonso, Luis ^a   Jacob, Sony ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Atrial fibrillation; Obesity; Reverse epidemiology

Indexed keywords

ANTIARRHYTHMIC AGENT;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 77953682224     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.11.026     Document Type: Article

References (53)

1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
2. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006) 119-125
3. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
4. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
5. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
6. Vasan R.S., Pencina M.J., Cobain M., et al. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med 143 (2005) 473-480
7. Dublin S., French B., Glazer N.L., et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 166 (2006) 2322-2328
8. Frost L., Hune L.J., and Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 118 (2005) 489-495
9. Wanahita N., Messerli F.H., Bangalore S., et al. Atrial fibrillation and obesity-results of a meta-analysis. Am Heart J 155 (2008) 310-315
10. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292 (2004) 2471-2477
11. Lauer M.S., Anderson K.M., Kannel W.B., and Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 266 (1991) 231-236
12. McGavock J.M., Victor R.G., Unger R.H., and Szczepaniak L.S. Adiposity of the heart, revisited. Ann Intern Med 144 (2006) 517-524
13. Mureddu G.F., de Simone G., Greco R., et al. Left ventricular filling pattern in uncomplicated obesity. Am J Cardiol 77 (1996) 509-514
14. Pelat M., Verwaerde P., Merial C., et al. Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension. Hypertension 34 (1999) 1066-1072
15. Pritchett A.M., Jacobsen S.J., Mahoney D.W., et al. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol 41 (2003) 1036-1043
16. Tsang T.S., Barnes M.E., Miyasaka Y., et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 29 (2008) 2227-2233
17. Kistler P.M., Sanders P., Morton J.B., et al. Effect of body mass index on defibrillation thresholds for internal cardioversion in patients with atrial fibrillation. Am J Cardiol 94 (2004) 370-372
18. Cha Y.M., Friedman P.A., Asirvatham S.J., et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation 117 (2008) 2583-2590
19. Ector J., Dragusin O., Adriaenssens B., et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 50 (2007) 234-242
20. Gami A.S., Hodge D.O., Herges R.M., et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 49 (2007) 565-571
21. Gami A.S., Pressman G., Caples S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 110 (2004) 364-367
22. Jongnarangsin K., Chugh A., Good E., et al. Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 19 (2008) 668-672
23. Kanagala R., Murali N.S., Friedman P.A., et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation 107 (2003) 2589-2594
24. Uretsky S., Messerli F.H., Bangalore S., et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 120 (2007) 863-870
25. Lavie C.J., Milani R.V., and Ventura H.O. Obesity, heart disease, and favorable prognosis-truth or paradox?. Am J Med 120 (2007) 825-826
26. Galal W., van Gestel Y.R., Hoeks S.E., et al. The obesity paradox in patients with peripheral arterial disease. Chest 134 (2008) 925-930
27. Lavie C.J., Ventura H.O., and Milani R.V. The "obesity paradox": is smoking/lung disease the explanation?. Chest 134 (2008) 896-898
28. Lavie C.J., Milani R.V., and Ventura H.O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53 (2009) 1925-1932
29. McAuley P., Myers J., Abella J., and Froelicher V. Body mass, fitness and survival in veteran patients: another obesity paradox?. Am J Med 120 (2007) 518-524
30. Kannel W.B., Abbott R.D., Savage D.D., and McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
31. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. Am J Cardiol 79 (1997) 1198-1202
32. AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 143 (2002) 991-1001
33. Wyse D.G., Waldo A.L., DiMarco J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
34. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158 (1998) 1855-1867
35. Horwich T.B., and Fonarow G.C. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 20 (2007) 549-553
36. Kalantar-Zadeh K., Block G., Humphreys M.H., and Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003) 793-808
37. Issac T.T., Dokainish H., and Lakkis N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50 (2007) 2021-2028
38. Lee S.H., Chen Y.C., Chen Y.J., et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci 80 (2007) 1806-1815
39. Sawaya S.E., Rajawat Y.S., Rami T.G., et al. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol 292 (2007) H1561-H1567
40. Mohamed-Ali V., Goodrick S., Bulmer K., et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 277 6 Pt 1 (1999) E971-E975
41. Novo G., Guttilla D., Fazio G., et al. The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS. Br J Clin Pharmacol 66 (2008) 345-351
42. Weber M.A., Neutel J.M., and Smith D.H. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol 37 (2001) 169-174
43. Rossi A., Enriquez-Sarano M., Burnett Jr. J.C., et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 35 (2000) 1256-1262
44. Rienstra M., Van Gelder I.C., Van den Berg M.P., et al. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP. Europace 8 (2006) 482-487
45. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
46. Rauchhaus M., Coats A.J., and Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet 356 9233 (2000) 930-933
47. Boos C.J., Lip G.Y., and Jilma B. Endotoxemia, inflammation, and atrial fibrillation. Am J Cardiol 100 (2007) 986-988
48. Horwich T.B., Fonarow G.C., Hamilton M.A., et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001) 789-795
49. Niraj A., Pradhan J., Fakhry H., et al. Severity of coronary artery disease in obese patients undergoing coronary angiography: "obesity paradox" revisited. Clin Cardiol 30 (2007) 391-396
50. Kalantar-Zadeh K., Anker S.D., Horwich T.B., and Fonarow G.C. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 101 11A (2008) 89E-103E
51. Kalantar-Zadeh K., and Kopple J.D. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 151 (2006) 57-69
52. Lavie C.J., Milani R.V., Artham S.M., Patel D.A., and Ventura H.O. The obesity paradox, weight loss, and coronary disease. Am J Med 122 (2009) 1106-1114
53. Lavie C.J., Osman A.F., Milani R.V., and Mehra M.R. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91 (2003) 891-894